NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

Rhea-AI Summary

NRx Pharmaceuticals (NASDAQ:NRXP) and its wholly-owned subsidiary HOPE Therapeutics have announced their participation in two major healthcare conferences in February 2025. The company's Founder, Chairman and CEO, Dr. Jonathan Javitt, will present a company update at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025, from 9:20 to 9:50 AM EST.

The presentation will be available through a live webcast on the NRX Events section of the company's Investor Relations website, with replay access for 30 days post-event. Additionally, management will attend the 2025 BIO CEO & Investor Conference and will be available for one-on-one meetings in New York from February 10th-12th, 2025.

• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10^th-12^th

WILMINGTON, Del., Feb. 6, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE"), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11^th-12^th.

The presentation is scheduled for Wednesday, February 12^th, from 9:20 – 9:50 AM EST. A live webcast will be accessible on NRX Events, within the Investor Relations section of the Company's website. A replay of the webcast will also be available for 30 days following the event.

Management will also be available for one-on-one meetings in New York from February 10^th-12^th. To schedule meetings in New York or at the BIO CEO & Investor Conference, please contact sebastian.gomez@astrpartners.com.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional  psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including risks arising from uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, HOPE Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off HOPE Therapeutics.  More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-inc-to-present-at-the-oppenheimer-35th-annual-healthcare-conference-on-february-12-2025-302369970.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When is NRx Pharmaceuticals (NRXP) presenting at the Oppenheimer Healthcare Conference?

NRx Pharmaceuticals is presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12th, 2025, from 9:20 to 9:50 AM EST.

How can investors access NRXP's Oppenheimer Conference presentation?

Investors can access the live webcast through the NRX Events section within the Investor Relations area of the company's website. A replay will be available for 30 days after the event.

What investor conferences is NRXP attending in February 2025?

NRXP is attending two conferences: the Oppenheimer 35th Annual Healthcare Life Sciences Conference and the 2025 BIO CEO & Investor Conference, both taking place February 10-12, 2025.

How can investors schedule one-on-one meetings with NRXP management in February 2025?

Investors can schedule one-on-one meetings with NRXP management in New York from February 10-12 by contacting sebastian.gomez@astrpartners.com.